IMG-007

DRUG6 trials

Sponsors

Inmagene LLC

Conditions

ADAlopecia Areata (AA)Atopic DermatitisAtopic Dermatitis EczemaAtopic dermatitisEczemaHealthy VolunteersModerate-to-severe Atopic Dermatitis

Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

TerminatedNCT05984784

Inmagene LLCAD, Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis

Start: 2023-08-09End: 2024-04-26Updated: 2025-11-06

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants

CompletedNCT06060977

Inmagene LLCAlopecia Areata (AA)

Start: 2023-09-25End: 2025-01-14Updated: 2026-02-09

Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants

TerminatedNCT06304740

Inmagene LLCHealthy Volunteers

Start: 2024-03-06End: 2024-08-28Updated: 2024-12-12

A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis

CompletedCTIS2023-505735-13-01

Inmagene LLCAtopic dermatitis

End: 2024-04-26Target: 40Updated: 2024-03-25

Phase 2

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

RecruitingNCT07037901

Inmagene LLCAtopic Dermatitis, Atopic Dermatitis Eczema, Eczema

Start: 2025-06-17End: 2028-08-01Target: 405Updated: 2026-08-12

Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis

Enrolling by invitationNCT07734415

Inmagene LLCAtopic Dermatitis, Atopic Dermatitis Eczema, Eczema

Start: 2026-06-05End: 2028-03-01Target: 400Updated: 2026-07-29